Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
Albireo Pharma (Nasdaq: ALBO) announced its participation in the Wainwright 3rd Annual Hepatitis B Virus Conference on October 18, 2022, where it will present and host investor meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Albireo Pharma (Nasdaq: ALBO) announced its participation in the Wainwright 3rd Annual Hepatitis B Virus Conference on October 18, 2022, where it will present and host investor meetings.
The company develops novel bile acid modulators for pediatric and adult liver diseases, with its lead product, Bylvay, FDA-approved for treating pruritus in progressive familial intrahepatic cholestasis (PFIC).
Bylvay is also undergoing trials for other liver diseases and is reimbursed in several European countries. The company has a strong pipeline, including ongoing studies for new treatments.
Details
News Market Reaction – ALBO
The recorded move for ALBO in the trading session of this news was -5.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on October 18, 2022. Albireo will be presenting and will host investor meetings.
A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay is reimbursed for the treatment of PFIC in Germany, England, Wales & Northern Ireland, Scotland, Italy, and Belgium. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.